Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dapoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 12/20 | 0.57 |
| ▸ | HTR1D | P28221 | 4/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapoxetine SCHEMBL29387056 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL29488428 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL30600097 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL34479 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL3672581 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL29352095 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL119037 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL9292059 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL27937194 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL27518070 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116715593-A | Optimized preparation method of dapoxetine hydrochloride and intermediate thereof | 北京悦康科创医药科技股份有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-111018723-B | Preparation and detection method of dapoxetine hydrochloride isomer impurity | 盖天力医药控股集团制药股份有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-104628584-A | High-purity dapoxetine preparation method suitable for industrialization | GUANGZHOU REGENEX CORP | 2015-05-20 | — | — | CN | claimed |
| WO-2014024205-A1 | A METHOD FOR PREPARING (S)-(+)-N, N-DIMETHYL-3-(NAPHTHALEN-1-YLOXY)-1-PHENYLPROPAN-1-AMINE OR ITS SALT AND INTERMEDIATE THEREOF | R L FINE CHEM (IN) | 2014-02-13 | — | — | WO | claimed |
| CN-102229538-B | Method for synthesizing dapoxetine | UNIV CENTRAL SOUTH | 2013-11-13 | — | — | CN | claimed |
| CN-101367739-B | Preparation of N,N-dimethyl-1-phenyl-3-(1-naphthoxy) propanamine | TAIZHOU VOCATIONAL & TECHNICAL COLLEGE | 2013-02-13 | — | — | CN | claimed |
| CN-102229538-A | Method for synthesizing dapoxetine | UNIV CENTRAL SOUTH | 2011-11-02 | — | — | CN | claimed |
| CN-101367739-A | Preparation of N,N-dimethyl-1-phenyl-3-(1-naphthoxy) propanamine | TAIZHOU VOCATIONAL & TECHNICAL (CN) | 2009-02-18 | — | — | CN | claimed |
| CN-100402488-C | Synthetic method for dapoxetine | SHANGHAI MAYAO CHEMICAL TECHNO (CN) | 2008-07-16 | — | — | CN | claimed |
| CN-1821212-A | Synthetic method for dapoxetine | MAYAO CHEMICAL TECHNOLOGY CO L (CN) | 2006-08-23 | — | — | CN | claimed |
| CN-1020093-C | 1-phenyl -3-naphthalenyloxypropanamines | LILLY CO ELI (US) | 1993-03-17 | — | — | CN | claimed |
| US-5135947-A | Treatment of depression, eating disorders, and alcoholism | ELI LILLY AND COMPANY (US) | 1992-08-04 | — | — | US | claimed |
| EP-0288188-B1 | 1-PHENYL-3-NAPHTHALENYLOXY-PROPANAMINES | ELI LILLY AND COMPANY (US) | 1991-10-16 | — | — | EP | claimed |
| EP-0288188-A1 | 1-Phenyl-3-naphthalenyloxy-propanamines | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | claimed |
| CN-88102018-A | 1-Phenyl-3-naphthyloxypropylamine | — | 1988-10-26 | — | — | CN | claimed |
| US-20250177770-A1 | SUBSTANCE USE DISORDER PREVENTION OR TREATMENT WITH LOW INTENSITY AND HIGH FREQUENCY MAGNETIC STIMULATION | ACTIPULSE NEUROSCIENCE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250152523-A1 | COMPOSITIONS FOR TREATMENT OF SEXUAL DYSFUNCTION | Woody's Medical LLC (US) | 2025-05-15 | — | — | US | disclosed |
| US-5135947-A | Treatment of depression, eating disorders, and alcoholism | ELI LILLY AND COMPANY (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0288188-B1 | 1-PHENYL-3-NAPHTHALENYLOXY-PROPANAMINES | ELI LILLY AND COMPANY (US) | 1991-10-16 | — | — | EP | disclosed |
| CN-88102018-A | 1-Phenyl-3-naphthyloxypropylamine | — | 1988-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152523-A1 | COMPOSITIONS FOR TREATMENT OF SEXUAL DYSFUNCTION | HTR5A, HTR2A, HTR1A | SLC6A4 34/4885HTR1B 9/4885HTR1D 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.